News & Events zu Ping An Biomedical Co Ltd (PASW)PASWPing An Biomedical Co Ltd

Ping An Biomedical Plans Acquisition of Three Patents from Future Biotechnology for $2M to $2.5M

Ping An Biomedical Co. announced its entry into a letter of intent with Future Biotechnology Group for the planned acquisition of three tumor cell-related medical technology patents covering areas including oncology diagnosis and treatment, cell detection and bioengineering, and biomarker and DNA probe technologies, for a consideration ranging from $2M to $2.5M. The planned acquisition shall be subject to a final acquisition agreement to be subsequently prepared and executed by the parties. The planned acquisition is intended to support the company's longer-term healthcare and biomedical R&D strategy and to establish a core intellectual property portfolio in oncology and biotechnology. The planned acquisition is intended to establish the company's position in tumor-related technology areas through targeted intellectual property. The company intends to gradually build a healthcare technology asset reserve that can support not only ownership of core intellectual properties, but also potential pathways such as internal development, collaboration, and licensing. The company expects this intellectual property reserve to provide foundational IP support for the subsequent commercialization and rollout of related healthcare businesses. Upon completion of the planned acquisition, the company intends to incorporate the patents into its healthcare technology IP reserve. Management plans to evaluate appropriate pathways for further development, which may include internal research and development, collaboration with partners, and/or licensing, subject to further assessment and applicable approvals. The company does not expect the planned acquisition, by itself, to generate material revenue in the near term; rather, it is intended as a foundational step to support the Company's longer-term healthcare and biomedical initiatives. The company notes that the planned transaction remains subject to due diligence, the negotiation and execution of definitive agreements, and applicable regulatory and contractual requirements. There can be no assurance that definitive agreements will be entered into or that the acquisition will be completed on the terms contemplated, or at all. The company may update this announcement following execution of definitive agreements to reflect the final terms.

Ping An Biomedical Signs Strategic Cooperation Agreement with Yuan Sheng Mei Yan

Ping An Biomedical signed a strategic cooperation agreement with Yuan Sheng Mei Yan Health Services. Under the agreement, Yuan Sheng Mei Yan will serve as a channel development service provider for Ping An Biomedical. The two parties will engage in deep cooperation in the broader health and wellness services market, with a shared goal of achieving cumulative sales of RMB 500M within three years. Under the cooperation arrangement, Yuan Sheng Mei Yan will leverage its comprehensive capabilities in health management, wellness services, and high-end customer operations to assist Ping An Biomedical in expanding product channels, promoting market outreach, and facilitating terminal service implementation. Ping An Biomedical, in turn, will draw on its strengths in biotechnology, health products, and research and development to provide product supply and technical support, helping both parties build a synergistic system spanning products, services, and market conversion.

Ping An Biomedical Shareholders Approve Capital Structure Overhaul

Ping An Biomedical announced that shareholders have approved all five resolutions at the company's 2026 Annual General Meeting, providing full authorization for an overhaul of its share capital structure, the introduction of high-vote Class B shares, a targeted share exchange with a major shareholder, and a large-scale share consolidation. Shareholders resolved by an ordinary resolution that, the Company authorised share capital of the Company be amended in the manner and sequence set out below with immediate effect: increasing the authorised share capital $50,000 divided into 800,000,000 ordinary shares of a nominal or par value of $0.0000625 each to $312,500 divided into 5,000,000,000 ordinary shares of a par value $0.0000625 each, by the addition of 4,200,000,000 ordinary shares of a par value $0.0000625 each; re-designating and re-classifying 4,900,000,000 authorised ordinary shares of a par value $0.0000625 each as 4,900,000,000 class A ordinary shares of par value $0.0000625 each, where the rights of the existing ordinary shares shall be the same as the Class A Shares; cancelling 100,000,000 authorised but unissued ordinary shares of a par value $0.0000625 each and create a new share class of 100,000,000 class B ordinary shares of par value $0.0000625 each, which will be entitled to one hundred votes per share, such that the authorised share capital of the Company shall become $312,500 divided into 4,900,000,000 class A ordinary shares of a par value $0.0000625 each and 100,000,000 class B ordinary shares of a par value $0.0000625 each. Shareholders resolved by a special resolution that the second amended and restated memorandum and articles of association of the Company, in the substantial form attached to the notice of annual general meeting and the proxy statement as Appendix 1 be adopted in substitution for and to the exclusion of the existing memorandum and articles of association of the Company in its entirety with effect upon the Authorised Share Capital Changes taking effect. Shareholders resolved by an ordinary resolution that, subject to the Authorised Share Capital Changes and Second Amended MAA taking effect and the Company's receipt of the consent to repurchase and application for shares duly executed by INSPIRETECH, the Board be and is hereby authorised to repurchase 12,250,000 Class A Shares from INSPIRETECH, all of which are fully paid shares, in consideration of and out of the proceeds of the Company's new issuance of 12,250,000 Class B Shares to INSPIRETECH. The arrangement effectively converts part of INSPIRETECH's holding into high-vote shares while keeping the number of shares held by that shareholder unchanged. Shareholders resolved by an ordinary resolution that, following the Authorised Share Capital Changes, and conditional upon the approval of the Board, with effect on a date within one calendar year after the conclusion of the Meeting to be determined by the Board: every one thousand then issued and unissued Class A Shares, or such lesser whole share amount of not being less than two as the Board may determine in its sole discretion, be consolidated into one class A ordinary share, where such Consolidated Class A Shares shall rank pari passu in all respect with each other and have the same rights and are subject to the same restrictions as the existing Class A Shares as set out in the Second Amended MAA; every one thousand then issued and unissued Class B Shares, or such lesser whole share amount of not being less than two as the Board may determine in its sole discretion, be consolidated into one class B ordinary share, where such Consolidated Class B Shares shall rank pari passu in all respect with each other and have the same rights and are subject to the same restrictions as the existing Class B Shares as set out in the Second Amended MAA. Shareholders resolved by a special resolution that subject to and immediately following the Share Consolidation being effected, the relevant provisions of the memorandum and articles of association of the Company then in effect be amended to reflect the Share Consolidation.